What you are comparing
Bioidentical is a chemistry word. It means the active molecule is identical to a hormone the human ovary or testis makes: 17-beta-estradiol, progesterone, testosterone. It does not mean plant-derived, custom-mixed, saliva-tested, or automatically safer. NAMS 2022 is explicit that the term can mislead because approved and compounded bioidentical products both exist.
Conventional HRT in public conversation often means the Women’s Health Initiative pair: oral conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA). Those are real, well-studied products. They are not the opposite of “natural” on a moral scale. They are also not the only conventional or approved options. Transdermal estradiol and oral micronized progesterone are widely used, FDA-approved, and bioidentical.
Clinics that sell compounded BHRT often set the comparison as “our natural hormones versus WHI synthetics.” ACOG says that marketing implies compounded products are more natural and therefore safer and more effective, without evidence. The honest comparison is molecule plus route plus manufacturing path. You can have approved bioidentical estradiol. You can have compounded bioidentical cream. You can have approved CEE. Those are three different objects.
This page is for people deciding among menopause therapies or reading a BHRT advertisement. It is not a reason to ignore vasomotor symptoms or to start hormones for “longevity optimization” without an indication. Endocrine Society guidance treats symptom treatment as individualized medical care.
How they differ
Molecule is a real difference. Estradiol is not CEE. Micronized progesterone is not MPA. Do not paste every WHI hazard onto every estrogen, and do not claim a cream erases thrombosis or breast-cancer considerations because the molecule matches serum estradiol. Route matters: oral estrogen has a different clotting conversation than many transdermal regimens in observational and guideline discussions, though individual risk still governs.
Manufacturing is a separate difference. Approved bioidentical products have inserts, manufacturing controls, and, where required, boxed warnings. Compounded BHRT may combine several hormones, use pellets or troches, and lack that package. NAMS lists dose variability, impurity, sterility, and missing risk labels as compounding problems. Chemistry identity does not fix those process issues.
Evidence base differs. NHLBI’s WHI pages summarize a large prevention trial that changed practice: combined CEE plus MPA increased coronary events, stroke, VTE, and invasive breast cancer in the studied older population. Estrogen-alone results differed for women without a uterus. Modern practice uses those data plus age-and-timing nuance. Custom mixes have testimonials and little comparative outcome data.
- Approved estradiol or progesterone: bioidentical molecule, labeled product.
- Approved CEE or MPA: non-identical molecules, large-trial history.
- Compounded BHRT: may be bioidentical chemistry, weaker regulation.
Who each option is for
Approved estradiol, often transdermal, plus micronized progesterone if you have a uterus, fits many people with bothersome vasomotor symptoms who are appropriate candidates by age, timing, and contraindication review. NAMS still calls hormone therapy the most effective treatment for those symptoms and for genitourinary syndrome when local therapy is chosen for that indication. That is medical HRT, not a boutique category.
Approved CEE, with or without a progestin depending on uterus status, can still be appropriate when a clinician and patient choose it. It is not obsolete by slogan. It is also not required. If you prefer a bioidentical labeled molecule, you can usually get one without compounding.
Compounded BHRT is for a defined gap—allergy, unavailable dose—or a fully informed preference after counseling that ACOG and NAMS recommend against routine use. It is a poor default for “optimization,” pellet insertion on visit one, or saliva-driven stacks of estriol, DHEA, and testosterone without a diagnosis.
No regimen is for you if you have unexplained bleeding, a hormone-sensitive cancer that has not been cleared with oncology, active VTE, or pregnancy. Those are clinician gates. A natural label does not open them.
Risks of choosing the wrong one
Treating WHI as a ban on all estrogen can leave severe flushes, sleep loss, and bone risk untreated in a recently menopausal candidate who might benefit from a labeled transdermal product. Treating WHI as irrelevant because your cream is bioidentical can hide clot and breast-risk counseling you still need. Both errors come from a false binary.
Choosing compounded BHRT to avoid “synthetics” can mean no endometrial protection, uneven dosing, and no insert that lists stroke and VTE. ACOG wants clinicians to say approved products are recommended when they exist. Paying more for the word bioidentical on a jar is not risk reduction.
Choosing CEE plus MPA without discussing alternatives can also be a mismatch if you wanted estradiol and micronized progesterone and those products fit. Shared decision-making includes molecule and route, not only a yes-or-no to hormones.
Pellets and multi-hormone troches add reversibility and stacking problems that the word bioidentical does not solve. If levels run high, you wait. If bleeding starts, you need a gynecologic plan, not another saliva kit.
How to decide
Separate three questions: What symptom or deficiency are we treating? Which molecule and route have the best risk story for me? Does that product exist in FDA-approved form? If yes, NAMS and ACOG want you there first. Bioidentical chemistry is already on many pharmacy shelves.
Ask the clinic to prescribe a labeled estradiol product if you refuse compounding. If they cannot, you have learned their business model. Ask how they protect the endometrium, how they screen for VTE and breast-cancer history, and how they monitor bleeding. Those process questions matter more than the adjective on the brochure.
Read WHI in context. NHLBI describes a prevention trial in a specific population, not a personality test for every estrogen. Combine that history with NAMS timing language and your personal contraindications. Do not outsource the decision to a “synthetic versus natural” graphic.
Keep indicated screening. Mammography, bleeding evaluation, and blood-pressure care do not become optional because the molecule matches human progesterone. Hormone therapy is a drug plan. Choose the labeled product that matches the indication when you can. Compound only with a reason you can say out loud.
Frequently Asked Questions
References
NAMS: 2022 Hormone Therapy Position Statement
https://menopause.org/wp-content/uploads/professional/nams-2022-hormone-therapy-position-statement.pdfACOG Clinical Consensus: Compounded Bioidentical Menopausal Hormone Therapy
https://www.acog.org/clinical/clinical-guidance/clinical-consensus/articles/2023/11/compounded-bioidentical-menopausal-hormone-therapyEndocrine Society: Treatment of Symptoms of the Menopause Clinical Practice Guideline
https://www.endocrine.org/clinical-practice-guidelines/treatment-of-symptoms-of-the-menopauseNIH NHLBI: Women’s Health Initiative (WHI)
https://www.nhlbi.nih.gov/science/womens-health-initiative-whi
Your Privacy Choices